BioCryst Pharmaceuticals (BCRX)
Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.
$8.49
vs last close−0.29 (−3.30%)
Something off on this page? Send us feedback.
Next report
Nov 2, 26
in 40 days
EPS estimate
$0.10
Revenue estimate
$165.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.13$0.00$0.02$0.06$1.12−$2.98$0.30Pending
Estimate−$0.07−$0.07$0.03$0.07$0.07$0.06$0.15$0.10
Surprise−85.7%+100.2%−33.3%−14.3%+1,500.0%−5,066.7%+94.6%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$131.5M$145.5M$163.4M$159.4M$406.6M$156.4M$218.3MPending
Estimate$126.6M$149.7M$149.8M$151.3M$151.3M$151.1M$183.3M$165.4M
Surprise+3.9%−2.8%+9.0%+5.3%+168.7%+3.5%+19.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.22 | — | — |
| Sep 2027 | $0.21 | — | — |
| Jun 2027 | $0.19 | — | — |
| Mar 2027 | $0.12 | — | — |
| Dec 2026 | $0.11 | — | — |
| Nov 2026 | $0.10 | — | — |
| Aug 2026 | $0.15 | $0.30 | +94.6% |
| May 2026 | $0.06 | −$2.98 | −5,066.7% |
| Feb 2026 | $0.07 | $1.12 | +1,500.0% |
| Nov 2025 | $0.07 | $0.06 | −14.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.22 | — | — | $197.6M | — | — | — |
| Sep 2027 | $0.21 | — | — | $195.2M | — | — | — |
| Jun 2027 | $0.19 | — | — | $189.9M | — | — | — |
| Mar 2027 | $0.12 | — | — | $167.5M | — | — | — |
| Dec 2026 | $0.11 | — | — | $169.2M | — | — | — |
| Nov 2, 2026 | $0.10 | — | — | $165.4M | — | — | — |
| Aug 5, 2026 | $0.15 | $0.30 | +94.6% | $183.3M | $218.3M | +19.1% | +0.6% |
| May 6, 2026 | $0.06 | −$2.98 | −5,066.7% | $151.1M | $156.4M | +3.5% | −2.2% |
| Feb 26, 2026 | $0.07 | $1.12 | +1,500.0% | $151.3M | $406.6M | +168.7% | +4.6% |
| Nov 3, 2025 | $0.07 | $0.06 | −14.3% | $151.3M | $159.4M | +5.3% | −6.3% |
| Aug 4, 2025 | |||||||
| May 5, 2025 | |||||||
| Feb 24, 2025 | |||||||
| Nov 4, 2024 | |||||||
| Aug 5, 2024 | |||||||
| May 6, 2024 | |||||||
| Feb 26, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 3, 2023 | |||||||
| Feb 21, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Mar 5, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 6, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 4, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 4, 2017 | |||||||
| Feb 27, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 23, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 7, 2015 |